DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Menu-Site Contactexpress Faqs Legends Companies Events Environment Memories Home-Biotech

Abcys | AB Science | Adocia | Advicenne Pharma | Affichem | Agate Bioservices | Aisa Therapeutics | Alfact Innovation | Alizé Pharma | Ambiotis | Anaconda Pharma | Aptys Pharmaceuticals | Ariana Pharmaceuticals | Aterovax | Atlantic Bone Screen | Aureus Sciences | B Cell Design | BioAlliance Pharma | Biocortech | BioCydex | Biométhodes | Biom'up | BioProtein Technologies | BioQuanta | BioSystems International | BMSystems (Bio-Modeling) | Carmat | Cellectis | Cellial Technologies | CellProthera | CellVax | Cerenis Therapeutics | CliniGenetics | Covalab | Cytheris | Cytoo | DBV Technologies | Diaxonhit | DNA Therapeutics | Domain Therapeutics | Dynabio | Edelris | Endotis Pharma | Epixis | ERYtech Pharma | Eye Tech Care | Flamel Technologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | Genomic Vision | GenoSafe | GenoScience Pharma | Genoscreen | GenOway | Genticel | GTP Technology | Helios Biosciences | Hemarina | Hybrigenics | Hyphen BioMed | Imagene | ImmunId | Immutep | Imstar | In-Cell-Art | Indicia Biotechnology | InGen Biosciences | Innate Pharma | InnaVirVax | Innovative Health Diagnostics | IntegraGen | Ipsogen | I-Stem | Karcinolys | Keosys | MABlife | Magnisense | Mapreg | Mauna Kea Technologies | Medesis Pharma | Mellitech | Metabolys | MilleGen | Murigenetics | NanoBiotix | Neorphys | Neovacs | Netris-Pharma | Neuronax | NewVectys | NicOx | Nokad | Nosopharm | NovAliX | NovoCIB | Novotec | Obe Therapy | Oligovax | Oncodesign | OriBase Pharma | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharnext | PhenoPro | Pherecydes Pharma | PolyIntell | Proteogenix | Protexel | PX'Therapeutics | Quantum Genomics | Rhenovia Pharma | ScarCell Therapeutics | Sisène Biotechnologies | Skuld-Tech | Stentys | Synapcell | Synprosis | Tc Land Expression | Theraclion | Theradiag | Theralpha | TheraVectys | Transgene | Trophos | TxCell | UROsphere | Vaxon Biotech | Vectalys | Vivalis | XenTech |

* AUREUS SCIENCES *


 

2000 - IDF
Paris
www.aureus-sciences.com

 

Contract, Knowledge
Key words: Bioinformatics, Knowledge management, Molecular modeling, Data structuring, AurSCOPE, AurPROFILE
Mission: to provide knowledge management solutions to accelerate life science discovery for third parties
Clients: Pharmaceutical industry, Biotechs
info@aureus-sciences.com

Age: 17 year(s)

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Start-up |
Managing Dir.-CEO: Theodosiou (Jason) [born 1959, Ph.D. organic chemistry, MBA Sup de Co Paris, ex-MDL Information Systems, EMAX/SciQuest, LION Bioscience, Elsevier
Sc.Dir.-CSO:
Dev.Dir.: Barberan (Olivier) [Ph.D.]
Fin.Dir.-CFO:
MktgComm:
BusDev:
Financers (Hist.): Bioam, AXA, FCJE (CDC), Matignon, OTC-AM
Note : the news thread astutely mixes own events and general R&D major findings external to the company

Turnover (M€) : 1.5 (2006)
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Data
Position : Subcontractor
Company confirm : none

 

History
DATEMILESTONETYPETIME
2011 .01 Company rename as Aureus Sciences (from Aureus Pharma) with no change in capital structure, and with a new, comprehensive life science applications webportal ORGL [11 years]
2010 .03 R&D partnering in Biointelligence R&D programme of € 118 Millions, designed to promote the use of systemic modeling and simulation tools to exploit biomedical databases and coordinated by Dassault Systèmes (with notably Sanofi-Aventis, Ipsen, Servier, Pierre Fabre, Bayer) R&D [10 years]
2010 .02 Licensing-out of DDI Project 2009 to Sanofi-Aventis LICOUT [10 years]
2008 .08 Launch of new software solution AurPROFILER (to rapidly evaluate target, cell and drug profiles using bio-assays) MKTG [8 years]
2007 .11 Licensing-out of Aurscope GPCR to BMS (renewal) LICOUT [7 years]
2002 .11 Licensing-out to Servier and Aventis LICOUT [2 years]
2006 .12 Nomination : Jason Theodosiou, new CEO, André Michel, founder, moved to supervisory board ORGN [6 years]
2004 .10 1st round-financing : 3.0 M€, by OTC A.M., AXA P.E., and previous shareholders RFINA [4 years]
2002 .01 Company (holding of Aureus as an SCP) founded by Dr André Michel ORGF [2 years]
2000 .09 Seed financing : 0.8 M€, by Bioam SFIN [0 year]
2000 .01 Company founded by Dr André Michel [born 1944, CEO, Ph.D. chemistry, Namur, ex-Servier, Neokimia] ORGF [0 year]

Actualisation / Updating: 26-Oct-2012

   


Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT



© J.H. Huber, Pharmaclient 2001-2017. Pour retourner à la page d'accueil Biotech: BIENVENUE !       Haut de page : légende